Postnatal thyroxine supplementation in infants less than 32 weeks' gestation: effects on pulmonary morbidity

Area of Science:

• Neonatal Medicine
• Endocrinology
• Pediatric Critical Care

Background:

• Transient hypothyroxinemia is observed in premature newborns and associated with adverse neonatal outcomes.
• Thyroid hormone levels are crucial for fetal and neonatal development, particularly in preterm infants.

Purpose of the Study:

• To investigate the efficacy of early thyroxine (T4) administration in improving outcomes for premature infants.
• To determine if T4 supplementation impacts the incidence of chronic lung disease and other prematurity-related complications.

Main Methods:

• A double-blind, placebo-controlled trial involving 49 newborns less than 32 weeks' gestation.
• Infants received either T4 (10 or 20 mcg/kg) or placebo within 48 hours of birth for 21 days.
• Chronic lung disease, defined as oxygen dependency at 28 days, was the primary outcome.

Main Results:

• No significant difference was observed in the incidence of chronic lung disease between the T4-supplemented and placebo groups.
• Rates of death, severe intraventricular hemorrhage (grade III-IV), periventricular leukomalacia, and sepsis were similar in both groups.
• Early T4 administration did not alter the occurrence of major neonatal morbidities.

Conclusions:

• Early thyroxine supplementation in preterm infants (less than 32 weeks' gestation) does not reduce the risk of chronic lung disease.
• The study concludes that T4 supplementation does not improve major neonatal outcomes or decrease complications associated with prematurity.
• Further research may be needed to explore alternative therapeutic strategies for managing transient hypothyroxinemia in neonates.